Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Precision medicine is the paradigm to develop treatments for patients based on molecular-targets that are effective in vivo when administered. In addition to identifying the molecular and ce...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
The GeoMx Digital Spatial Profiling technology enables high-plex RNA and protein profiling of any region within any tissue type. This workshop will highlight the latest developments toward e...
The evolution of clinical trial design in oncology reflects the current clinical paradigm of personalized medicine, weighing both histology and molecularly-defined biomarkers as the pillars...
The evolution of clinical trial design in oncology reflects the current clinical paradigm of personalized medicine, weighing both histology and molecularly-defined biomarkers as the pillars...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
Molecular profiling is key in precision oncology research and whilst the tissue testing has become a routine, liquid biopsy might provide a non-invasive alternative when tissue biopsy is ina...
The development of molecular targeted therapy is one of the breakthroughs in oncology field. Molecular profiling of the tumor becomes mandatory in the routine clinical practice to select the...
NSCLC in Asia has high prevalence of EGFR Mutation and this is the case in Malaysia as well. This presentation will provide Malaysia’s approach in implementation of NGS in their 1st li...
The prevalence of EGFR mutation rate positivity in NSCLC is high in Asia, and this is the case in Malaysia as well. This presentation will provide Malaysia’s approach in implementation...
Date: April 29, 2020 Time: 8:00AM PDT, 11:00AM EDT Single cell genomics and other next generation sequencing applications depend strongly on adequate upstream sample preparation. Results can...
The International Council for Standardization in Haematology (ICSH) is a nonprofit organization dedicated to providing open-access guidance documents to enhance the quality of laboratory tes...
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
In recent years Nanotherapeutics has revolutionized the healthcare strategies and envisioned to have a tremendous impact to offer better health facilities. It involves design, fabrication, r...
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for 10-20% of all breast cancer cases diagnosed annually in the U.S.1. Despite its prevalence, TNBC remains resist...
DATE: April 14, 2020 TIME: 9:00am PDT, 12:00pm EDT Besides being Gibco Cell Culture Heroes, what do Vivek, Sandra, Daisy, Ameet and Kristine all have in common? They are all stuck at home fo...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Precision medicine is the paradigm to develop treatments for patients based on molecular-targets that are effective in vivo when administered. In addition to identifying the molecular and ce...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
The GeoMx Digital Spatial Profiling technology enables high-plex RNA and protein profiling of any region within any tissue type. This workshop will highlight the latest developments toward e...
The evolution of clinical trial design in oncology reflects the current clinical paradigm of personalized medicine, weighing both histology and molecularly-defined biomarkers as the pillars...
The evolution of clinical trial design in oncology reflects the current clinical paradigm of personalized medicine, weighing both histology and molecularly-defined biomarkers as the pillars...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
Molecular profiling is key in precision oncology research and whilst the tissue testing has become a routine, liquid biopsy might provide a non-invasive alternative when tissue biopsy is ina...
The development of molecular targeted therapy is one of the breakthroughs in oncology field. Molecular profiling of the tumor becomes mandatory in the routine clinical practice to select the...
NSCLC in Asia has high prevalence of EGFR Mutation and this is the case in Malaysia as well. This presentation will provide Malaysia’s approach in implementation of NGS in their 1st li...
The prevalence of EGFR mutation rate positivity in NSCLC is high in Asia, and this is the case in Malaysia as well. This presentation will provide Malaysia’s approach in implementation...
Date: April 29, 2020 Time: 8:00AM PDT, 11:00AM EDT Single cell genomics and other next generation sequencing applications depend strongly on adequate upstream sample preparation. Results can...
The International Council for Standardization in Haematology (ICSH) is a nonprofit organization dedicated to providing open-access guidance documents to enhance the quality of laboratory tes...
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
In recent years Nanotherapeutics has revolutionized the healthcare strategies and envisioned to have a tremendous impact to offer better health facilities. It involves design, fabrication, r...
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for 10-20% of all breast cancer cases diagnosed annually in the U.S.1. Despite its prevalence, TNBC remains resist...
DATE: April 14, 2020 TIME: 9:00am PDT, 12:00pm EDT Besides being Gibco Cell Culture Heroes, what do Vivek, Sandra, Daisy, Ameet and Kristine all have in common? They are all stuck at home fo...
Follow
